Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
暂无分享,去创建一个
Hong Ma | Krystal J Alligood | G. Owens | N. Spector | Hong Ma | David W Rusnak | Wenle Xia | Lei-hua Liu | W. Xia | Neil L Spector | D. Rusnak | Gary Owens | Lei-Hua Liu | R. Mullin | B. Keith | Robert J Mullin | Barry R Keith | K. Alligood
[1] Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. , 2001, Bioorganic & medicinal chemistry letters.
[2] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. O'hare,et al. New model of ErbB‐2 over‐expression in human mammary luminal epithelial cells , 1999, International journal of cancer.
[4] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[5] J. Willson,et al. Autocrine Transforming Growth Factor α Provides a Growth Advantage to Malignant Cells by Facilitating Re-entry into the Cell Cycle from Suboptimal Growth States* , 1998, The Journal of Biological Chemistry.
[6] D. Stern,et al. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.
[7] R. Daly,et al. Take your partners, please--signal diversification by the erbB family of receptor tyrosine kinases. , 1999, Growth factors.
[8] W. Denny,et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[9] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[10] Monilola A. Olayioye,et al. ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.
[11] A. Tari,et al. Serum predominantly activates MAPK and Akt kinases in EGFR‐ and ErbB2‐over‐expressing cells, respectively , 2000, International journal of cancer.
[12] J. Mendelsohn,et al. Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 , 1999, Oncogene.
[13] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[14] E. Wagner,et al. Strain-dependent epithelial defects in mice lacking the EGF receptor. , 1995, Science.
[15] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[16] Takashi Tsuruo,et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.
[17] A. Ullrich,et al. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[18] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[19] N. Goldstein,et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] R. Weinberg,et al. The pathway to signal achievement , 1993, Nature.
[21] A. Ullrich,et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells , 1987, Cell.
[22] R. K Srivastava,et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.
[23] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[24] D. Stern,et al. Specificity within the EGF family/ErbB receptor family signaling network , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] M. Greene,et al. Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.
[26] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[27] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[28] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[29] J. Willson,et al. Aberrant Regulation of Transforming Growth Factor-α during the Establishment of Growth Arrest and Quiescence of Growth Factor Independent Cells* , 1998, The Journal of Biological Chemistry.
[30] L. Williams,et al. An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. , 1994, Science.
[31] P. Dennis,et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.
[32] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[33] H. Earp,et al. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research , 1995, Breast Cancer Research and Treatment.
[34] K. Herrup,et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.
[35] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[36] M. Luther,et al. Involvement of pp60c-src with two major signaling pathways in human breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Levitzki,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Science.